Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC189 in Advanced Solid Tumors With RAS Mutations
NCT07836036Phase 1Not yet recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASKC189 in solid tumor, sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events and Serious Adverse Events at 30 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ASKC189
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07836036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836036.